2025-523872-22-00RecruitingPhase 1
Research into the safety of a new agent (NRG5051) in healthy adults and patients with Parkinson's disease or ALS
Source: EU CTIS (euclinicaltrials.eu) · Last updated 9 Jul 2026
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 118 (estimated)
- First submitted
- 6 Oct 2025
- Start date
- 18 Nov 2025
- Lead sponsor
- Nrg Therapeutics Limited
- EU CT number
- 2025-523872-22-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 118
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre for Human Drug Research | Leiden | Netherlands | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.